Skip to main content
SpringerLink
Log in

Pulmonary Hypertension in Adults with Congenital Heart Disease

  • Living reference work entry
  • First Online:
Pediatric Cardiology

  • 41 Accesses

Abstract

Pulmonary hypertension (PH) complicates congenital heart disease (CHD) in up to 10% of cases and impacts quality of life and survival of these patients. Different forms of PH related to CHD arise due to the complex and diverse range of underlying cardiac anatomy and physiology observed in this patient group. Distinguishing between different types of PH is important to guide diagnosis and management, and PH related to CHD is best diagnosed and managed in centers specializing in both CHD and PH. This chapter provides an overview of the current classification of PH, pathophysiology, diagnosis, and optimal management in patients with CHD. This includes the spectrum of pulmonary arterial hypertension (PAH) related to CHD, from Eisenmenger syndrome to PAH after defect repair. Evidence-based treatment strategies include supportive measures, avoidance of potentially harmful practices, use of pulmonary arterial hypertension (PAH) therapy and heart failure therapy, and management of emergencies including hemoptysis and infective endocarditis. Decisions around operability in patients with unrepaired shunts and PAH and the role of “treat-and-repair” strategies are mainly based on expert opinion and require individual specialist assessment. Expert input is also required in special instances of PH related to CHD, such as pulmonary vasculopathy after Fontan-type repair, segmental PH, disease related to peripheral pulmonary stenoses, and PH complicating Down syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Galiè N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46:903–75.

    Article  PubMed  Google Scholar 

  2. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, Williams PG, Souza R. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53:1801913.

    Article  CAS  PubMed  Google Scholar 

  3. Rosenzweig EB, Abman SH, Adatia I, Beghetti M, Bonnet D, Haworth S, Ivy DD, Berger RMF. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J. 2019; https://doi.org/10.1183/13993003.01916-2018.

  4. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, et al. ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). Eur Heart J. 2022; 43(38):3618–731. https://doi.org/10.1093/eurheartj/ehac237

  5. Dimopoulos K, Wort SJ, Gatzoulis MA. Pulmonary hypertension related to congenital heart disease: a call for action. Eur Heart J. 2014;35:691–700.

    Google Scholar 

  6. Frescura C, Thiene G, Gagliardi M, Mazzucco A, Pellegrino P, Daliento L, Biscaglia S, Carminati M, Gallucci V. Is lung biopsy useful for surgical decision making in congenital heart disease? Eur J Cardiothorac Surg. 1991;5:118–23.

    Article  CAS  PubMed  Google Scholar 

  7. Konstantinides S, Geibel A, Olschewski M, Görnandt L, Roskamm H, Spillner G, Just H, Kasper W. A comparison of surgical and medical therapy for atrial septal defect in adults. N Engl J Med. 1995;333:5.

    Article  Google Scholar 

  8. Constantine A, Dimopoulos K. Evaluating a strategy of PAH therapy pre-treatment in patients with atrial septal defects and pulmonary arterial hypertension to permit safe repair (“treat-and-repair”). Int J Cardiol. 2019;291:142–4.

    Article  PubMed  Google Scholar 

  9. Constantine A, Dimopoulos K, Opotowsky AR. Congenital heart disease and pulmonary hypertension. Cardiol Clin. 2020;38:445–56.

    Article  PubMed  Google Scholar 

  10. Manes A, Palazzini M, Leci E, Bacchi Reggiani ML, Branzi A, Galiè N. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. Eur Heart J. 2014;35:716–24.

    Article  PubMed  Google Scholar 

  11. Alonso-Gonzalez R, Lopez-Guarch CJ, Subirana-Domenech MT, et al. Pulmonary hypertension and congenital heart disease: an insight from the REHAP National Registry. Int J Cardiol. 2015;184:717–23.

    Article  PubMed  Google Scholar 

  12. Dimopoulos K, Diller G-P, Opotowsky AR, et al. Definition and management of segmental pulmonary hypertension. J Am Heart Assoc. 2018; https://doi.org/10.1161/JAHA.118.008587.

  13. Zhu N, Welch CL, Wang J, et al. Rare variants in SOX17 are associated with pulmonary arterial hypertension with congenital heart disease. Genome Med. 2018;10:56.

    Article  PubMed  Google Scholar 

  14. Hall SM, Haworth SG. Onset and evolution of pulmonary vascular disease in young children: abnormal postnatal remodelling studied in lung biopsies. J Pathol. 1992;166:183–93.

    Article  CAS  PubMed  Google Scholar 

  15. Dimopoulos K, Diller G-P, editors. Pulmonary hypertension in adult congenital heart disease. Springer International Publishing; 2017.

    Google Scholar 

  16. Humbert M, Guignabert C, Bonnet S, et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J. 2018; https://doi.org/10.1183/13993003.01887-2018.

  17. Heath D, Helmholz HF, Burchell HB, Dushane JW, Edwards JE. Graded pulmonary vascular changes and hemodynamic findings in cases of atrial and ventricular septal defect and patent ductus arteriosus. Circulation. 1958;18:1155–66.

    Article  CAS  PubMed  Google Scholar 

  18. Galambos C, Sims-Lucas S, Abman SH, Cool CD. Intrapulmonary bronchopulmonary anastomoses and plexiform lesions in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2016;193:574–6.

    Article  CAS  PubMed  Google Scholar 

  19. Wagenvoort CA. Morphological substrate for the reversibility and irreversibility of pulmonary hypertension. Eur Heart J. 1988;9(Suppl J):7–12.

    Article  PubMed  Google Scholar 

  20. Wagenvoort CA, Wagenvoort N, Draulans-Noë Y. Reversibility of plexogenic pulmonary arteriopathy following banding of the pulmonary artery. J Thorac Cardiovasc Surg. 1984;87:876–86.

    Article  CAS  PubMed  Google Scholar 

  21. Ghigna M-R, Guignabert C, Montani D, et al. BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension. Eur Respir J. 2016;48:1668–81.

    Article  CAS  PubMed  Google Scholar 

  22. Naeije R, Manes A. The right ventricle in pulmonary arterial hypertension. Eur Respir Rev. 2014;23:476–87.

    Article  PubMed  Google Scholar 

  23. Vonk Noordegraaf A, Chin KM, Haddad F, Hassoun PM, Hemnes AR, Hopkins SR, Kawut SM, Langleben D, Lumens J, Naeije R. Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update. Eur Respir J. 2019;53:1801900.

    Article  PubMed  Google Scholar 

  24. Rosenblueth A, Alanis J, Lopez E, Rubio R. The adaptation of ventricular muscle to different circulatory conditions. Arch Int Physiol Biochim. 1959;67:358–73.

    CAS  PubMed  Google Scholar 

  25. Naeije R, Brimioulle S, Dewachter L. Biomechanics of the right ventricle in health and disease (2013 Grover conference series). Pulm Circ. 2014;4:395–406.

    Article  PubMed  Google Scholar 

  26. Drakopoulou M, Nashat H, Kempny A, et al. Arrhythmias in adult patients with congenital heart disease and pulmonary arterial hypertension. Heart. 2018;104:1963–9.

    Article  CAS  PubMed  Google Scholar 

  27. Hopkins WE. The remarkable right ventricle of patients with Eisenmenger syndrome. Coron Artery Dis. 2005;16:19–25.

    Article  PubMed  Google Scholar 

  28. Baruteau A-E, Belli E, Boudjemline Y, Laux D, Lévy M, Simonneau G, Carotti A, Humbert M, Bonnet D. Palliative Potts shunt for the treatment of children with drug-refractory pulmonary arterial hypertension: updated data from the first 24 patients. Eur J Cardiothorac Surg. 2015;47:e105–10.

    Article  PubMed  Google Scholar 

  29. Moceri P, Kempny A, Liodakis E, et al. Physiological differences between various types of Eisenmenger syndrome and relation to outcome. Int J Cardiol. 2015;179:455–60.

    Article  PubMed  Google Scholar 

  30. Hjortshøj CMS, Kempny A, Jensen AS, et al. Past and current cause-specific mortality in Eisenmenger syndrome. Eur Heart J. 2017;38:2060–7.

    Article  PubMed  Google Scholar 

  31. Kempny A, Dimopoulos K, Uebing A, Moceri P, Swan L, Gatzoulis MA, Diller G-P. Reference values for exercise limitations among adults with congenital heart disease. Relation to activities of daily life –single centre experience and review of published data. Eur Heart J. 2012;33:1386–1396

    Google Scholar 

  32. Dimopoulos K, Okonko DO, Diller G-P, et al. Abnormal ventilatory response to exercise in adults with congenital heart disease relates to cyanosis and predicts survival. Circulation. 2006;113:2796–802.

    Article  PubMed  Google Scholar 

  33. Broberg C, Ujita M, Babu-Narayan S, Rubens M, Prasad SK, Gibbs JSR, Gatzoulis MA. Massive pulmonary artery thrombosis with haemoptysis in adults with Eisenmenger’s syndrome: a clinical dilemma. Heart. 2004;90:e63.

    Article  CAS  PubMed  Google Scholar 

  34. Silversides CK, Granton JT, Konen E, Hart MA, Webb GD, Therrien J. Pulmonary thrombosis in adults with Eisenmenger syndrome. J Am Coll Cardiol. 2003;42:1982–7.

    Article  PubMed  Google Scholar 

  35. Broberg CS, Ujita M, Prasad S, et al. Pulmonary arterial thrombosis in Eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity. J Am Coll Cardiol. 2007;50:634–42.

    Article  PubMed  Google Scholar 

  36. Prapa M, McCarthy KP, Dimopoulos K, Sheppard MN, Krexi D, Swan L, Wort SJ, Gatzoulis MA, Ho SY. Histopathology of the great vessels in patients with pulmonary arterial hypertension in association with congenital heart disease: large pulmonary arteries matter too. Int J Cardiol. 2013;168:2248–54.

    Article  PubMed  Google Scholar 

  37. Opotowsky AR, Landzberg MJ, Beghetti M. The exceptional and far-flung manifestations of heart failure in Eisenmenger syndrome. Heart Fail Clin. 2014;10:91–104.

    Article  PubMed  Google Scholar 

  38. Broberg CS, Jayaweera AR, Diller GP, Prasad SK, Thein SL, Bax BE, Burman J, Gatzoulis MA. Seeking optimal relation between oxygen saturation and hemoglobin concentration in adults with cyanosis from congenital heart disease. Am J Cardiol. 2011;107:595–9.

    Article  CAS  PubMed  Google Scholar 

  39. Ammash N, Warnes CA. Cerebrovascular events in adult patients with cyanotic congenital heart disease. J Am Coll Cardiol. 1996;28:768–72.

    Article  CAS  PubMed  Google Scholar 

  40. Blanche C, Alonso-Gonzalez R, Uribarri A, Kempny A, Swan L, Price L, Wort SJ, Beghetti M, Dimopoulos K. Use of intravenous iron in cyanotic patients with congenital heart disease and/or pulmonary hypertension. Int J Cardiol. 2018;267:79–83.

    Article  PubMed  Google Scholar 

  41. Tay ELW, Peset A, Papaphylactou M, et al. Replacement therapy for iron deficiency improves exercise capacity and quality of life in patients with cyanotic congenital heart disease and/or the Eisenmenger syndrome. Int J Cardiol. 2011;151:307–12.

    Article  PubMed  Google Scholar 

  42. Lill MC, Perloff JK, Child JS. Pathogenesis of thrombocytopenia in cyanotic congenital heart disease. Am J Cardiol. 2006;98:254–8.

    Article  CAS  PubMed  Google Scholar 

  43. Waldow HC, Westhoff-Bleck M, Widera C, Templin C, von Depka M. Acquired von Willebrand syndrome in adult patients with congenital heart disease. Int J Cardiol. 2014;176:739–45.

    Article  PubMed  Google Scholar 

  44. Griesman JD, Karahalios DS, Prendergast CJ. Hematologic changes in cyanotic congenital heart disease: a review. Prog Pediatr Cardiol. 2020;56:101193.

    Article  Google Scholar 

  45. Hultcrantz M, Björkholm M, Dickman PW, Landgren O, Derolf ÅR, Kristinsson SY, Andersson TML. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med. 2018;168:317–25.

    Article  PubMed  Google Scholar 

  46. Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018:25255.

    Google Scholar 

  47. Baumgartner H, Bonhoeffer P, De Groot NMS, et al. ESC guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J. 2010;31:2915–57.

    Article  PubMed  Google Scholar 

  48. Martínez-Quintana E, Rodríguez-González F. Fontan circulation: beyond cardiopulmonary assessment. Pneumologia. 2016;65:233. [ISSN 2067-2993].

    PubMed  Google Scholar 

  49. Martin-Garcia AC, Arachchillage DR, Kempny A, et al. Platelet count and mean platelet volume predict outcome in adults with Eisenmenger syndrome. Heart. 2018;104:45–50.

    Article  CAS  PubMed  Google Scholar 

  50. Dickinson CJ. The aetiology of clubbing and hypertrophic osteoarthropathy. Eur J Clin Investig. 1993;23:330–8.

    Article  CAS  Google Scholar 

  51. Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC guidelines for the management of infective endocarditis: the Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC)Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36:3075–128.

    Article  PubMed  Google Scholar 

  52. Walter W, Taubert KA, Michael G, et al. Prevention of infective endocarditis. Circulation. 2007;116:1736–54.

    Article  Google Scholar 

  53. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications. Circulation. 2015;132:1435–86.

    Article  CAS  PubMed  Google Scholar 

  54. Dimopoulos K, Diller G-P, Koltsida E, et al. Prevalence, predictors, and prognostic value of renal dysfunction in adults with congenital heart disease. Circulation. 2008;117:2320–8.

    Article  PubMed  Google Scholar 

  55. Perloff JK. Systemic complications of cyanosis in adults with congenital heart disease. Hematologic derangements, renal function, and urate metabolism. Cardiol Clin. 1993;11:689–99.

    Article  CAS  PubMed  Google Scholar 

  56. Perloff JK, Rosove MH, Child JS, Wright GB. Adults with cyanotic congenital heart disease: hematologic management. Ann Intern Med. 1988;109:406–13.

    Article  CAS  PubMed  Google Scholar 

  57. Ross EA, Perloff JK, Danovitch GM, Child JS, Canobbio MM. Renal function and urate metabolism in late survivors with cyanotic congenital heart disease. Circulation. 1986;73:396–400.

    Article  CAS  PubMed  Google Scholar 

  58. Lui GK, Saidi A, Bhatt AB, et al. Diagnosis and management of noncardiac complications in adults with congenital heart disease: a scientific statement from the American Heart Association. Circulation. 2017;136:e348–92.

    Article  PubMed  Google Scholar 

  59. Rodríguez-Hernández JL, Rodríguez-González F, Riaño-Ruiz M, Martínez-Quintana E. Risk factors for hyperuricemia in congenital heart disease patients and its relation to cardiovascular death. Congenit Heart Dis. 2018;13:655–62.

    Article  PubMed  Google Scholar 

  60. Kempny A, Dimopoulos K, Tutarel O, Tutaj A, Marchewka D, Piatek P, Swan L, Diller GP, Wort SJ, Gatzoulis MA. Prognostic value of ECG parameters in patients with Eisenmenger syndrome. Eur Heart J. 2013; https://doi.org/10.1093/eurheartj/eht308.P2103.

  61. Kaemmerer H, Fratz S, Braun SL, Koelling K, Eicken A, Brodherr-Heberlein S, Pietrzik K, Hess J. Erythrocyte indexes, iron metabolism, and hyperhomocysteinemia in adults with cyanotic congenital cardiac disease. Am J Cardiol. 2004;94:825–8.

    Article  CAS  PubMed  Google Scholar 

  62. Asrani SK, Asrani NS, Freese DK, Phillips SD, Warnes CA, Heimbach J, Kamath PS. Congenital heart disease and the liver. Hepatology. 2012;56:1160–9.

    Article  PubMed  Google Scholar 

  63. Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723–50.

    Article  PubMed  Google Scholar 

  64. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.

    Article  Google Scholar 

  65. Galiè N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, Chiossi E, Kusic-Pajic A, Simonneau G. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371:2093–100.

    Article  PubMed  Google Scholar 

  66. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J. 2007;30:338–44.

    Article  CAS  PubMed  Google Scholar 

  67. Diller G-P, Alonso-Gonzalez R, Kempny A, et al. B-type natriuretic peptide concentrations in contemporary Eisenmenger syndrome patients: predictive value and response to disease targeting therapy. Heart. 2012;98:736–42.

    Article  CAS  PubMed  Google Scholar 

  68. Scognamiglio G, Kempny A, Price LC, et al. C-reactive protein in adults with pulmonary arterial hypertension associated with congenital heart disease and its prognostic value. Heart. 2014;100:1335–41.

    Article  CAS  PubMed  Google Scholar 

  69. Pierce MJ, LaFranchi SH, Pinter JD. Characterization of thyroid abnormalities in a large cohort of children with Down syndrome. Horm Res Paediatr. 2017;87:170–8.

    Article  CAS  PubMed  Google Scholar 

  70. Theofilogiannakos EK, Giannakoulas G, Ziakas A, Karvounis HI, Styliadis IH. Pseudohypoglycemia in a patient with the Eisenmenger syndrome. Ann Intern Med. 2010;152:407–8.

    Article  PubMed  Google Scholar 

  71. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53:1573–619.

    Article  PubMed  Google Scholar 

  72. Dimopoulos K, Condliffe R, Tulloh RMR, et al. Echocardiographic screening for pulmonary hypertension in congenital heart disease. J Am Coll Cardiol. 2018;72:2778–88.

    Article  PubMed  Google Scholar 

  73. Moceri P, Dimopoulos K, Liodakis E, et al. Echocardiographic predictors of outcome in Eisenmenger syndrome. Circulation. 2012;126:1461–8.

    Article  PubMed  Google Scholar 

  74. Fine NM, Libo C, Bastiansen PM, Frantz RP, Pellikka PA, Oh JK, Kane GC. Outcome prediction by quantitative right ventricular function assessment in 575 subjects evaluated for pulmonary hypertension. Circ Cardiovasc Imaging. 2013;6:711–21.

    Article  PubMed  Google Scholar 

  75. Myriam A, Sweatt AJ, Aymami MC, et al. Right heart end-systolic remodeling index strongly predicts outcomes in pulmonary arterial hypertension. Circ Cardiovasc Imaging. 2017;10:e005771.

    Article  Google Scholar 

  76. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111–7.

    Article  Google Scholar 

  77. Kempny A, Dimopoulos K, Alonso-Gonzalez R, et al. Six-minute walk test distance and resting oxygen saturations but not functional class predict outcome in adult patients with Eisenmenger syndrome. Int J Cardiol. 2013;168:4784–9.

    Article  PubMed  Google Scholar 

  78. Kempny A, Hjortshøj CS, Gu H, et al. Predictors of death in contemporary adult patients with Eisenmenger syndrome: a multicenter study. Circulation. 2017;135:1432–40.

    Article  PubMed  Google Scholar 

  79. Inuzuka R, Diller G-P, Borgia F, et al. Comprehensive use of cardiopulmonary exercise testing identifies adults with congenital heart disease at increased mortality risk in the medium term. Circulation. 2012;125:250–9.

    Article  PubMed  Google Scholar 

  80. Alonso-Gonzalez R, Borgia F, Diller G-P, et al. Abnormal lung function in adults with congenital heart disease: prevalence, relation to cardiac anatomy, and association with survival. Circulation. 2013;127:882–90.

    Article  PubMed  Google Scholar 

  81. Diller G-P, Okonko DO, Uebing A, Dimopoulos K, Bayne S, Sutton R, Francis DP, Gatzoulis MA. Impaired heart rate response to exercise in adult patients with a systemic right ventricle or univentricular circulation: prevalence, relation to exercise, and potential therapeutic implications. Int J Cardiol. 2009;134:59–66.

    Article  PubMed  Google Scholar 

  82. Flamm MMD, Cohn KE, Hancock EW. Measurement of systemic cardiac output at rest and exercise in patients with atrial septal defect. Am J Cardiol. 1969;23:258–65.

    Article  CAS  PubMed  Google Scholar 

  83. Miller HC, Brown DJ, Miller GA. Comparison of formulae used to estimate oxygen saturation of mixed venous blood from caval samples. Br Heart J. 1974;36:446–51.

    Article  CAS  PubMed  Google Scholar 

  84. D’Alto M, Dimopoulos K, Coghlan JG, Kovacs G, Rosenkranz S, Naeije R. Right heart catheterization for the diagnosis of pulmonary hypertension: controversies and practical issues. Heart Fail Clin. 2018;14:467–77.

    Article  PubMed  Google Scholar 

  85. Hamilton WF, Riley RL, Attyah AM, et al. Comparison of the Fick and dye injection methods of measuring the cardiac output in man. Am J Physiol. 1948; https://doi.org/10.1152/ajplegacy.1948.153.2.309.

  86. Hoeper MM, Maier R, Tongers J, Niedermeyer J, Hohlfeld JM, Hamm M, Fabel H. Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension. Am J Respir Crit Care Med. 1999;160:535–41.

    Article  CAS  PubMed  Google Scholar 

  87. Bejal P, Quail MA, Steeden JA, Andrea MK, Freddy O, Taylor AM, Ingram S-N, Graham D, Shahin M, Vivek M. Real-time magnetic resonance assessment of septal curvature accurately tracks acute hemodynamic changes in pediatric pulmonary hypertension. Circ Cardiovasc Imag. 2014;7:706–13.

    Article  Google Scholar 

  88. Baim DS. Grossman’s cardiac catheterization, angiography, and intervention. Lippincott Williams & Wilkins; 2006.

    Google Scholar 

  89. Balzer DT, Kort HW, Day RW, et al. Inhaled nitric oxide as a preoperative test (INOP test I): the INOP Test Study Group. Circulation. 2002;106:I76–81.

    Article  PubMed  Google Scholar 

  90. Kempny A, Dimopoulos K, Fraisse A, Diller G-P, Price LC, Rafiq I, McCabe C, Gatzoulis MA, Wort SJ. Blood viscosity and its relevance to the diagnosis and management of pulmonary hypertension. J Am Coll Cardiol. 2019;73:2636–42.

    Article  Google Scholar 

  91. Budts W, Börjesson M, Chessa M, van Buuren F, Trigo Trindade P, Corrado D, Heidbuchel H, Webb G, Holm J, Papadakis M. Physical activity in adolescents and adults with congenital heart defects: individualized exercise prescription. Eur Heart J. 2013;34:3669–74.

    Article  PubMed  Google Scholar 

  92. Yentis SM, Steer PJ, Plaat F. Eisenmenger’s syndrome in pregnancy: maternal and fetal mortality in the 1990s. BJOG Int J Obstet Gynaecol. 1998;105:921–2.

    Article  CAS  Google Scholar 

  93. Weiss BM, Zemp L, Seifert B, Hess OM. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J Am Coll Cardiol. 1998;31:1650–7.

    Google Scholar 

  94. Silversides CK, Grewal J, Mason J, Sermer M, Kiess M, Rychel V, Wald RM, Colman JM, Siu SC. Pregnancy outcomes in women with heart disease: the CARPREG II study. J Am Coll Cardiol. 2018;71:2419–30.

    Google Scholar 

  95. Gonzaga LRA, Matos-Garcia BC, Rocco IS, et al. Effects of acute oxygen supplementation on functional capacity and heart rate recovery in Eisenmenger syndrome. Int J Cardiol. 2017;231:110–4.

    Google Scholar 

  96. Sandoval J, Aguirre JS, Pulido T, Martinez-Guerra ML, Santos E, Alvarado P, Rosas M, Bautista E. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med. 2001;164:1682–7.

    Article  CAS  PubMed  Google Scholar 

  97. Harinck E, Hutter PA, Hoorntje TM, Simons M, Benatar AA, Fischer JC, de Bruijn D, Meijboom EJ. Air travel and adults with cyanotic congenital heart disease. Circulation. 1996;93:272–6.

    Article  CAS  PubMed  Google Scholar 

  98. Broberg CS, Uebing A, Cuomo L, Thein SL, Papadopoulos MG, Gatzoulis MA. Adult patients with Eisenmenger syndrome report flying safely on commercial airlines. Heart. 2007;93:1599–603.

    Article  PubMed  Google Scholar 

  99. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148–57.

    Article  PubMed  Google Scholar 

  100. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369:809–18.

    Article  CAS  PubMed  Google Scholar 

  101. Ghofrani H-A, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369:330–40.

    Article  CAS  PubMed  Google Scholar 

  102. Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373:2522–33.

    Article  CAS  PubMed  Google Scholar 

  103. Rosenkranz S, Ghofrani H-A, Beghetti M, Ivy D, Frey R, Fritsch A, Weimann G, Saleh S, Apitz C. Riociguat for pulmonary arterial hypertension associated with congenital heart disease. Heart. 2015;101:1792–9.

    Article  CAS  PubMed  Google Scholar 

  104. Galiè N, Barberà JA, Frost AE, et al. Initial use of Ambrisentan plus Tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373:834–44.

    Article  PubMed  Google Scholar 

  105. Beghetti M, Channick RN, Chin KM, et al. Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. Eur J Heart Fail. 2019;21:352–9.

    Article  CAS  PubMed  Google Scholar 

  106. Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger RMF, Lauer A, Chiossi E, Landzberg M, Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114:48–54.

    Article  PubMed  Google Scholar 

  107. Chau EMC, Fan KYY, Chow WH. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol. 2007;120:301–5.

    Article  PubMed  Google Scholar 

  108. Garg N, Sharma MK, Sinha N. Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship. Int J Cardiol. 2007;120:306–13.

    Article  PubMed  Google Scholar 

  109. Zhang Z-N, Jiang X, Zhang R, et al. Oral sildenafil treatment for Eisenmenger syndrome: a prospective, open-label, multicentre study. Heart. 2011;97:1876–81.

    Article  CAS  PubMed  Google Scholar 

  110. Tay ELW, Papaphylactou M, Diller GP, et al. Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy. Int J Cardiol. 2011;149:372–6.

    Article  PubMed  Google Scholar 

  111. Singh TP, Rohit M, Grover A, Malhotra S, Vijayvergiya R. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J. 2006;151:851.e1–5.

    Article  PubMed  Google Scholar 

  112. Mukhopadhyay S, Nathani S, Yusuf J, Shrimal D, Tyagi S. Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger syndrome – a randomized, placebo-controlled, double-blind crossover study. Congenit Heart Dis. 2011;6:424–31.

    Article  PubMed  Google Scholar 

  113. Fernandes SM, Newburger JW, Lang P, Pearson DD, Feinstein JA, Gauvreau K, Landzberg MJ. Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology. Am J Cardiol. 2003;91:632–5.

    Article  CAS  PubMed  Google Scholar 

  114. Nashat H, Kempny A, Harries C, Dormand N, Alonso-Gonzalez R, Price LC, Gatzoulis MA, Dimopoulos K, Wort SJ. A single-centre, placebo-controlled, double-blind randomised cross-over study of nebulised iloprost in patients with Eisenmenger syndrome: a pilot study. Int J Cardiol. 2020;299:131–5.

    Article  PubMed  Google Scholar 

  115. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002;165:800–4.

    Article  PubMed  Google Scholar 

  116. Vis JC, Duffels MG, Mulder P, de Bruin-Bon RHACM, Bouma BJ, Berger RMF, Hoendermis ES, van Dijk APJ, Mulder BJM. Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease. Int J Cardiol. 2013;164:64–9.

    Article  PubMed  Google Scholar 

  117. Diller G-P, Alonso-Gonzalez R, Dimopoulos K, et al. Disease targeting therapies in patients with Eisenmenger syndrome: response to treatment and long-term efficiency. Int J Cardiol. 2013;167:840–7.

    Article  PubMed  Google Scholar 

  118. Apostolopoulou SC, Manginas A, Cokkinos DV, Rammos S. Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study. Heart. 2007;93:350–4.

    Article  CAS  PubMed  Google Scholar 

  119. Gatzoulis MA, Landzberg M, Beghetti M, et al. Evaluation of Macitentan in patients with Eisenmenger syndrome: results from the randomized, controlled MAESTRO study. Circulation. 2019;139:51–63.

    Article  CAS  PubMed  Google Scholar 

  120. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, Diehl JH, Crow J, Long W. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Ann Intern Med. 1990;112:485–91.

    Article  CAS  PubMed  Google Scholar 

  121. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous Epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296–301.

    Article  CAS  PubMed  Google Scholar 

  122. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation. 1999;99:1858–65.

    Article  CAS  PubMed  Google Scholar 

  123. Kingman M, Archer-Chicko C, Bartlett M, Beckmann J, Hohsfield R, Lombardi S. Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension. Pulm Circ. 2017;7:598–608.

    Article  CAS  PubMed  Google Scholar 

  124. Ivy DD, Doran AK, Smith KJ, et al. Short- and long-term effects of inhaled Iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol. 2008;51:161–9.

    Article  CAS  PubMed  Google Scholar 

  125. Cha KS, Cho KI, Seo JS, Choi JH, Park YH, Yang DH, Hong GR, Kim DS. Effects of inhaled iloprost on exercise capacity, quality of life, and cardiac function in patients with pulmonary arterial hypertension secondary to congenital heart disease (the Eisenmenger syndrome) (from the EIGER study). Am J Cardiol. 2013;112:1834–9.

    Article  CAS  PubMed  Google Scholar 

  126. Yang SI, Chung WJ, Jung SH, Choi DY. Effects of inhaled Iloprost on congenital heart disease with Eisenmenger syndrome. Pediatr Cardiol. 2012;33:744–8.

    Article  PubMed  Google Scholar 

  127. Skoro-Sajer N, Gerges C, Balint OH, et al. Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension. Heart. 2018;104:1195–9.

    Article  CAS  PubMed  Google Scholar 

  128. D’Alto M, Constantine A, Balint OH, Romeo E, Argiento P, Ablonczy L, Skoro-Sajer N, Giannakoulas G, Dimopoulos K. The effects of parenteral prostacyclin therapy as add-on treatment to oral compounds in Eisenmenger syndrome. Eur Respir J. 2019; https://doi.org/10.1183/13993003.01401-2019.

  129. Olsson KM, Marion D, Ardeschir GH, et al. Anticoagulation and survival in pulmonary arterial hypertension. Circulation. 2014;129:57–65.

    Article  CAS  PubMed  Google Scholar 

  130. Oechslin E. Hematological management of the cyanotic adult with congenital heart disease. Int J Cardiol. 2004;97:109–15.

    Article  PubMed  Google Scholar 

  131. Yang H, Bouma BJ, Dimopoulos K, et al. Non-vitamin K antagonist oral anticoagulants (NOACs) for thromboembolic prevention, are they safe in congenital heart disease? Results of a worldwide study. Int J Cardiol. 2020;299:123–30.

    Article  CAS  PubMed  Google Scholar 

  132. Takken T, Giardini A, Reybrouck T, Gewillig M, Hövels-Gürich H, Longmuir P, McCrindle B, Paridon S, Hager A. Recommendations for physical activity, recreation sport, and exercise training in paediatric patients with congenital heart disease: a report from the Exercise, Basic & Translational Research Section of the European Association of Cardiovascular Prevention and Rehabilitation, the European Congenital Heart and Lung Exercise Group, and the Association for European Paediatric Cardiology. Eur J Prev Cardiol. 2012;19:1034–65.

    Article  CAS  PubMed  Google Scholar 

  133. Pelliccia A, Sharma S, Gati S, et al. 2020 ESC guidelines on sports cardiology and exercise in patients with cardiovascular disease: the task force on sports cardiology and exercise in patients with cardiovascular disease of the European Society of Cardiology (ESC). Eur Heart J. 2020;00:1–80.

    Google Scholar 

  134. Price LC, Dimopoulos K, Marino P, et al. The CRASH report: emergency management dilemmas facing acute physicians in patients with pulmonary arterial hypertension. Thorax. 2017;72:1035–45.

    Article  PubMed  Google Scholar 

  135. Horigome H, Iwasaki N, Anno I, Kurachi S, Kurachi K. Magnetic resonance imaging of the brain and haematological profile in adult cyanotic congenital heart disease without stroke. Heart. 2006;92:263–5.

    Article  CAS  PubMed  Google Scholar 

  136. Dimopoulos K, Peset A, Gatzoulis MA. Evaluating operability in adults with congenital heart disease and the role of pretreatment with targeted pulmonary arterial hypertension therapy. Int J Cardiol. 2008;129:163–71.

    Article  PubMed  Google Scholar 

  137. Huang Z, Fan Z, Sun J, Li W, Gao Y, Quan Y, Geng Y, Niu Y, Wu B. The short- and medium-term results of transcatheter closure of atrial septal defect with severe pulmonary arterial hypertension. Heart Vessel. 2012;27:603–9.

    Article  Google Scholar 

  138. Bradley EA, Ammash N, Martinez SC, et al. “Treat-to-close”: non-repairable ASD-PAH in the adult: results from the North American ASD-PAH (NAAP) Multicenter Registry. Int J Cardiol. 2019; https://doi.org/10.1016/j.ijcard.2019.03.056.

  139. Bruch L, Winkelmann A, Sonntag S, Scherf F, Rux S, Grad MO, Kleber FX. Fenestrated occluders for treatment of ASD in elderly patients with pulmonary hypertension and/or right heart failure. J Interv Cardiol. 2008;21:44–9.

    Article  PubMed  Google Scholar 

  140. Janjua AM, Saleem K, Khan I, Rashid A, Khan AA, Hussain A. Double flap patch closure of VSD with elevated pulmonary vascular resistance: an experience at AFIC/NIHD. J Coll Physicians Surg Pak. 2011;21:197–201.

    PubMed  Google Scholar 

  141. Talwar S, Keshri VK, Choudhary SK, Gupta SK, Ramakrishnan S, Saxena A, Kothari SS, Juneja R, Kumar G, Airan B. Unidirectional valved patch closure of ventricular septal defects with severe pulmonary arterial hypertension: hemodynamic outcomes. J Thorac Cardiovasc Surg. 2014;148:2570–5.

    Article  PubMed  Google Scholar 

  142. Rich S, Lam W. Atrial septostomy as palliative therapy for refractory primary pulmonary hypertension. Am J Cardiol. 1983;51:1560–1.

    Article  CAS  PubMed  Google Scholar 

  143. Nihill MR, O’Laughlin MP, Mullins CE. Effects of atrial septostomy in patients with terminal cor pulmonale due to pulmonary vascular disease. Catheter Cardiovasc Diagn. 1991;24:166–72.

    Article  CAS  Google Scholar 

  144. Rothman A, Beltran D, Kriett JM, Smith C, Wolf P, Jamieson SW. Graded balloon dilation atrial septostomy as a bridge to lung transplantation in pulmonary hypertension. Am Heart J. 1993;125:1763–6.

    Article  CAS  PubMed  Google Scholar 

  145. D’Alto M, Romeo E, Argiento P, Correra A, Santoro G, Gaio G, Sarubbi B, Calabrò R, Russo MG. Hemodynamics of patients developing pulmonary arterial hypertension after shunt closure. Int J Cardiol. 2013;168:3797–801.

    Article  PubMed  Google Scholar 

  146. Van De Bruaene A, La Gerche A, Prior DL, Voigt J-U, Delcroix M, Budts W. Pulmonary vascular resistance as assessed by bicycle stress echocardiography in patients with atrial septal defect type secundum. Circ Cardiovasc Imaging. 2011;4:237–45.

    Article  PubMed  Google Scholar 

  147. Van De Bruaene A, De Meester P, Buys R, Vanhees L, Delcroix M, Voigt J-U, Budts W. Right ventricular load and function during exercise in patients with open and closed atrial septal defect type secundum. Eur J Prev Cardiol. 2013;20:597–604.

    Article  PubMed  Google Scholar 

  148. Santos M, Systrom D, Epstein SE, John A, Ruiz G, Landzberg MJ, Opotowsky AR. Impaired exercise capacity following atrial septal defect closure: an invasive study of the right heart and pulmonary circulation. Pulm Circ. 2014;4:630–7.

    Article  PubMed  Google Scholar 

  149. Mitchell MB, Campbell DN, Ivy D, Boucek MM, Sondheimer HM, Pietra B, Das BB, Coll JR. Evidence of pulmonary vascular disease after heart transplantation for Fontan circulation failure. J Thorac Cardiovasc Surg. 2004;128:693–702.

    Article  PubMed  Google Scholar 

  150. Egbe AC, Connolly HM, Miranda WR, Ammash NM, Hagler DJ, Veldtman GR, Borlaug BA. Hemodynamics of Fontan failure: the role of pulmonary vascular disease. Circ Heart Fail. 2017; https://doi.org/10.1161/CIRCHEARTFAILURE.117.004515.

  151. Henaine R, Vergnat M, Bacha EA, Baudet B, Lambert V, Belli E, Serraf A. Effects of lack of pulsatility on pulmonary endothelial function in the Fontan circulation. J Thorac Cardiovasc Surg. 2013;146:522–9.

    Article  CAS  PubMed  Google Scholar 

  152. Alsaied T, Alsidawi S, Allen CC, Faircloth J, Palumbo JS, Veldtman GR. Strategies for thromboprophylaxis in Fontan circulation: a meta-analysis. Heart. 2015;101:1731–7.

    Article  CAS  PubMed  Google Scholar 

  153. Khambadkone S, Li J, de Leval MR, Cullen S, Deanfield JE, Redington AN. Basal pulmonary vascular resistance and nitric oxide responsiveness late after Fontan-type operation. Circulation. 2003;107:3204–8.

    Article  CAS  PubMed  Google Scholar 

  154. Giardini A, Balducci A, Specchia S, Gargiulo G, Bonvicini M, Picchio FM. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J. 2008;29:1681–7.

    Article  CAS  PubMed  Google Scholar 

  155. Takahashi K, Mori Y, Yamamura H, Nakanishi T, Nakazawa M. Effect of beraprost sodium on pulmonary vascular resistance in candidates for a Fontan procedure: a preliminary study. Pediatr Int. 2003;45:671–5.

    Article  CAS  PubMed  Google Scholar 

  156. Ovaert C, Thijs D, Dewolf D, Ottenkamp J, Dessy H, Moons P, Gewillig M, Mertens L. The effect of bosentan in patients with a failing Fontan circulation. Cardiol Young. 2009;19:331–9.

    Article  PubMed  Google Scholar 

  157. Hirono K, Yoshimura N, Taguchi M, Watanabe K, Nakamura T, Ichida F, Miyawaki T. Bosentan induces clinical and hemodynamic improvement in candidates for right-sided heart bypass surgery. J Thorac Cardiovasc Surg. 2010;140:346–51.

    Article  CAS  PubMed  Google Scholar 

  158. Goldberg DJ, French B, McBride MG, Marino BS, Mirarchi N, Hanna BD, Wernovsky G, Paridon SM, Rychik J. Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: a randomized, double-blind, placebo-controlled, crossover trial. Circulation. 2011;123:1185–93.

    Article  CAS  PubMed  Google Scholar 

  159. Schuuring MJ, Vis JC, van Dijk APJ, van Melle JP, Vliegen HW, Pieper PG, Sieswerda GT, de Bruin-Bon RHACM, Mulder BJM, Bouma BJ. Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial. Eur J Heart Fail. 2013;15:690–8.

    Article  CAS  PubMed  Google Scholar 

  160. Rhodes J, Ubeda-Tikkanen A, Clair M, Fernandes SM, Graham DA, Milliren CE, Daly KP, Mullen MP, Landzberg MJ. Effect of inhaled iloprost on the exercise function of Fontan patients: a demonstration of concept. Int J Cardiol. 2013;168:2435–40.

    Article  PubMed  Google Scholar 

  161. Hebert A, Mikkelsen UR, Thilen U, Idorn L, Jensen AS, Nagy E, Hanseus K, Sørensen KE, Søndergaard L. Bosentan improves exercise capacity in adolescents and adults after Fontan operation: the TEMPO (treatment with endothelin receptor antagonist in Fontan patients, a randomized, placebo-controlled, double-blind study measuring peak oxygen consumption) study. Circulation. 2014;130:2021–30.

    Article  CAS  PubMed  Google Scholar 

  162. Goldberg DJ, Zak V, Goldstein BH, et al. Results of the Fontan Udenafil Exercise Longitudinal (FUEL) Trial. Circulation. 2019; https://doi.org/10.1161/CIRCULATIONAHA.119.044352.

  163. Clift P, Berger F, Sondergaard L, Antonova P, Disney P, Nicolarsen J, Thambo JB, Tomkiewicz Pajak L, Wang JK, Schophuus Jensen A, Burgess G, Efficace M, Friberg M, Lassen C, d’Udekem Y, RUBATO Study Team. The efficacy and safety of macitentan in Fontan-palliated patients: results of the 52-week randomised, placebo-controlled RUBATO trial. Eur Heart J. 2022;43(Suppl 2):ehac544.1560. https://doi.org/10.1093/eurheartj/ehac544.1560.

  164. Constantine A, Dimopoulos K, Jenkins P, Tulloh RMR, Condliffe R, Jansen K, Chung NAY, Oliver J, Parry H, Fitzsimmons S, Walker N, Wort SJ, Papaioannou V, von Klemperer K, Clift P. Use of pulmonary arterial hypertension therapies in patients with a Fontan circulation: current practice across the United Kingdom. J Am Heart Assoc. 2022;11(1):e023035. https://doi.org/10.1161/JAHA.121.023035.

  165. Montanaro C, Merola A, Kempny A, et al. The outcome of adults born with pulmonary atresia: high morbidity and mortality irrespective of repair. Int J Cardiol. 2019;280:61–6.

    Google Scholar 

  166. Schuuring MJ, Bouma BJ, Cordina R, Gatzoulis MA, Budts W, Mullen MP, Vis JC, Celermajer D, Mulder BJM. Treatment of segmental pulmonary artery hypertension in adults with congenital heart disease. Int J Cardiol. 2013;164:106–10.

    Article  PubMed  Google Scholar 

  167. Lim ZS, Vettukattill JJ, Salmon AP, Veldtman GR. Sildenafil therapy in complex pulmonary atresia with pulmonary arterial hypertension. Int J Cardiol. 2008;129:339–43.

    Article  PubMed  Google Scholar 

  168. Alagille D, Estrada A, Hadchouel M, Gautler M, Odièvre M, Dommergues JP. Syndromic paucity of interlobular bile ducts (Alagille syndrome or arteriohepatic dysplasia): review of 80 cases. J Pediatr. 1987;110:195–200.

    Article  CAS  PubMed  Google Scholar 

  169. Ghofrani H-A, Simonneau G, D’Armini AM, et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respir Med. 2017;5:785–94.

    Article  CAS  PubMed  Google Scholar 

  170. Stout KK, Broberg CS, Book WM, et al. Chronic heart failure in congenital heart disease: a scientific statement from the American Heart Association. Circulation. 2016;133:770–801.

    Article  PubMed  Google Scholar 

  171. Harada G, Takeuchi D, Inai K, Shinohara T, Nakanishi T. Prevalence and risk factors of sleep apnoea in adult patients with CHD. Cardiol Young. 2019;29:71–7.

    Article  CAS  PubMed  Google Scholar 

  172. Hjortshøj CS, Jensen AS, Christensen JAE, Jennum P, Søndergaard L. Sleep-disordered breathing in Eisenmenger Syndrome. Int J Cardiol. 2016;214:23–4.

    Article  PubMed  Google Scholar 

  173. Körten M-A, Helm PC, Abdul-Khaliq H, Baumgartner H, Kececioglu D, Schlensak C, Bauer UMM, Diller G-P, Investigators CN for CHD. Eisenmenger syndrome and long-term survival in patients with Down syndrome and congenital heart disease. Heart. 2016;102:1552–7.

    Article  PubMed  Google Scholar 

  174. Simpson R, Oyekan AA, Ehsan Z, Ingram DG. Obstructive sleep apnea in patients with Down syndrome: current perspectives. Nat Sci Sleep. 2018;10:287–93.

    Article  PubMed  Google Scholar 

  175. Gatzoulis MA, Landzberg M, Beghetti M, Berger RM, Efficace M, Gesang S, He J, Papadakis K, Pulido T, Galiè N. Evaluation of Macitentan in patients with Eisenmenger syndrome. Circulation. 2019;139:51–63.

    Article  CAS  PubMed  Google Scholar 

  176. Vis JC, Thoonsen H, Duffels MG, de Bruin-Bon RA, Huisman SA, van Dijk AP, Hoendermis ES, Berger RM, Bouma BJ, Mulder BJ. Six-minute walk test in patients with Down syndrome: validity and reproducibility. Arch Phys Med Rehabil. 2009;90:1423–7.

    Article  PubMed  Google Scholar 

  177. Duffels MGJ, Vis JC, van Loon RLE, Berger RMF, Hoendermis ES, van Dijk APJ, Bouma BJ, Mulder BJM. Down patients with Eisenmenger syndrome: is bosentan treatment an option? Int J Cardiol. 2009;134:378–83.

    Article  PubMed  Google Scholar 

  178. D’Alto M, Romeo E, Argiento P, et al. Therapy for pulmonary arterial hypertension due to congenital heart disease and Down’s syndrome. Int J Cardiol. 2013;164:323–6.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK

    Konstantinos Dimopoulos & Andrew Constantine

  2. National Heart and Lung Institute, Imperial College London, London, United Kingdom

    Konstantinos Dimopoulos & Andrew Constantine

Authors
  1. Konstantinos Dimopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew Constantine
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Konstantinos Dimopoulos .

Editor information

Editors and Affiliations

  1. Lurie Children's Hospital, Northwestern Memorial Hospital, Chicago, IL, USA

    Ra-id Abdulla

  2. Lurie Children's Hospital of Chicago, Northwestern Memorial Hospital, Chicago, USA

    Stuart Berger

  3. Lurie Children's Hospital of Chicago, Northwestern Memorial Hospital, Chicago, USA

    Carl Backer

  4. King's College, University College London, London, UK

    Robert Anderson

  5. Weill Cornell Medical College, Cornell University, New York, USA

    Ralf Holzer

  6. University of Amsterdam, Amsterdam, Noord-Holland, The Netherlands

    Nico Blom

  7. Lurie Children's Hospital of Chicago, Northwestern Memorial Hospital, Chicago, IL, USA

    Joshua Robinson

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Dimopoulos, K., Constantine, A. (2023). Pulmonary Hypertension in Adults with Congenital Heart Disease. In: Abdulla, Ri., et al. Pediatric Cardiology. Springer, Cham. https://doi.org/10.1007/978-3-030-42937-9_106-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-42937-9_106-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-42937-9

  • Online ISBN: 978-3-030-42937-9

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation